The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Targeted genomic rearrangements using CRISPR/Cas technology
Open accessAbstract
Genomic rearrangements are frequently observed in cancer cells but have been difficult to generate in a highly specific manner for functional analysis. Here we report the application of CRISPR/Cas technology to successfully generate several types of chromosomal rearrangements implicated as driver events in lung cancer, including the CD74-ROS1 translocation event and the EML4-ALK and KIF5B-RET inversion events. Our results demonstrate that Cas9-induced DNA breaks promote efficient rearrangement between pairs of targeted loci, providing a highly tractable approach for the study of genomic rearrangements. Genomic rearrangements have important functional consequences for cancer. Here, Choi and Meyerson use CRISPR/Cas technology to generate translocations and inversions that are known drivers of lung cancer, and demonstrate the utility of this technology for studying the role of genomic rearrangements in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“In addition, while off-target recognition and cleavage by Cas9 may result in non-specific chromosomal rearrangements, these unintended effects could be minimized by generating DSBs using a ‘double-nicking’ strategy 20, 21 or targeting with shorter 17nt sgRNAs which exhibit greater specificity 22 .”
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752 · cited 1×
“In addition, while off-target recognition and cleavage by Cas9 may result in non-specific chromosomal rearrangements, these unintended effects could be minimized by generating DSBs using a ‘double-nicking’ strategy 20, 21 or targeting with shorter 17nt sgRNAs which exhibit greater specificity 22 .”
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Cited by
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
CRISPR/Cas9 in Genome Editing and Beyond
Wang, H., La Russa, M., & Qi, L. S. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014607 · Cited by 1,110
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640
Large chromosomal deletions and heritable small genetic changes induced by CRISPR/Cas9 in rice
Zhou, H., Liu, B., Weeks, D. P., Spalding, M. H., & Yang, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku806 · Cited by 598
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
Cullot, G., Boutin, J., Toutain, J., Prat, F., Pennamen, P., Rooryck, C., Teichmann, M., Rousseau, E., Lamrissi-Garcia, I., Guyonnet-Duperat, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09006-2 · Cited by 474
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
Expanding the Biologist’s Toolkit with CRISPR-Cas9
Sternberg, S. H., & Doudna, J. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.032 · Cited by 404
Applications of the CRISPR-Cas9 system in cancer biology
Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405
Billon, P., Bryant, E. E., Joseph, S. A., Nambiar, T. S., Hayward, S. B., Rothstein, R., & Ciccia, A. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.008 · Cited by 363
Chromosomal Translocations in Human Cells Are Generated by Canonical Nonhomologous End-Joining
Ghezraoui, H., Piganeau, M., Renouf, B., Renaud, J.-B., Sallmyr, A., Ruis, B., Oh, S., Tomkinson, A. E., Hendrickson, E. A., Giovannangeli, C., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.002 · Cited by 351
“Molecu Cas9 has also been used in HEK293 cells to induce a translocation found in lung tumors (Choi and Meyerson, 2014).”
MethodA Mouse Geneticist’s Practical Guide to CRISPR Applications
Singh, P., Schimenti, J. C., & Bolcun-Filas, E. (2015) · Genetics · doi:10.1534/genetics.114.169771 · Cited by 305
Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair
Gutschner, T., Haemmerle, M., Genovese, G., Draetta, G. F., & Chin, L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.019 · Cited by 299
CRISPR-mediated live imaging of genome editing and transcription
Wang, H., Nakamura, M., Abbott, T. R., Zhao, D., Luo, K., Yu, C., Nguyen, C. M., Lo, A., Daley, T. P., La Russa, M., et al. (2019) · Science · doi:10.1126/science.aax7852 · Cited by 299
Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line
Essletzbichler, P., Konopka, T., Santoro, F., Chen, D., Gapp, B. V., Kralovics, R., Brummelkamp, T. R., Nijman, S. M. B., & Bürckstümmer, T. (2014) · Genome Research · doi:10.1101/gr.177220.114 · Cited by 277
Peterson, B. A., Haak, D. C., Nishimura, M. T., Teixeira, P. J. P. L., James, S. R., Dangl, J. L., & Nimchuk, Z. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162169 · Cited by 172
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives
Lee, J. S., Grav, L. M., Lewis, N. E., & Faustrup Kildegaard, H. (2015) · Biotechnology Journal · doi:10.1002/biot.201500082 · Cited by 117
De Masi, C., Spitalieri, P., Murdocca, M., Novelli, G., & Sangiuolo, F. (2020) · Human Genomics · doi:10.1186/s40246-020-00276-2 · Cited by 91
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.030 · Cited by 30
Rapid interrogation of cancer cell of origin through CRISPR editing
Feng, W., Cao, Z., Lim, P. X., Zhao, H., Luo, H., Mao, N., Lee, Y. S., Rivera, A. A., Choi, D., Wu, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110344118 · Cited by 25
Metadata
- Authors
- Choi, P. S., & Meyerson, M.
- Venue
- Nature Communications
- Published
- 2014-04-24
- Volume
- 5
- Issue
- 1
- Pages
- 3728-3728
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2043972484
- Cited by
- 309
- References
- 11
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.